Browsing ICR Divisions by title
Now showing items 4056-4075 of 4685
-
Systemic Treatment for Adults with Synovial Sarcoma.
(2018-03-07)Opinion statement Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic ... -
Systemic treatment in adult uterine sarcomas.
(2018-02)Uterine sarcomas (US) are rare mesenchymal tumours of the uterus and are divided mainly into uterine leiomyosarcoma (uLMS), low grade endometrial stromal sarcoma (LG-ESS), high grade endometrial stromal sarcoma (HG-ESS), ... -
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network.
(ELSEVIER, 2022-06-01)BACKGROUND: Clear cell sarcoma (CCS) is a translocated aggressive malignancy with a high incidence of metastases and poor prognosis. There are few studies describing the activity of systemic therapy in CCS. We report a ... -
Systems biology of the motif-mediated cell cycle interactome
(Institute of Cancer Research (University Of London), 2024-05-09)The eukaryotic cell cycle is a tightly controlled series of events leading to cell division. It relies on a complex network of regulatory proteins, serving as checkpoints to oversee DNA replication and ensure orderly cell ... -
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
(NATL ACAD SCIENCES, 2021-04-27)Cancer cells can survive chemotherapy-induced stress, but how they recover from it is not known. Using a temporal multiomics approach, we delineate the global mechanisms of proteotoxic stress resolution in multiple myeloma ... -
T-cell Prolymphocytic Leukemia.
(W B SAUNDERS CO-ELSEVIER INC, 2017-04-01)T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy. T-PLL can be distinguished from other lymphoid diseases by the evaluation and integration of clinical features, morphology, immunophenotyping, ... -
T2-adjusted computed diffusion-weighted imaging: A novel method to enhance tumour visualisation.
(PERGAMON-ELSEVIER SCIENCE LTD, 2016-12-01)PURPOSE: To introduce T2-adjusted computed DWI (T2-cDWI), a method that provides synthetic images at arbitrary b-values and echo times (TEs) that improve tissue contrast by removing or increasing T2 contrast in diffusion-weighted ... -
T2-Weighted 4D Magnetic Resonance Imaging for Application in Magnetic Resonance-Guided Radiotherapy Treatment Planning.
(LIPPINCOTT WILLIAMS & WILKINS, 2017-10-01)OBJECTIVES: The aim of this study was to develop and verify a method to obtain good temporal resolution T2-weighted 4-dimensional (4D-T2w) magnetic resonance imaging (MRI) by using motion information from T1-weighted 4D ... -
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
(DOVE MEDICAL PRESS LTD, 2021-03-08)Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ... -
A tailored approach to horizon scanning for cancer medicines.
(ELSEVIER SCI LTD, 2023-12-01)BACKGROUND: Horizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis ... -
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
(MASSACHUSETTS MEDICAL SOC, 2018-07-12)BACKGROUND: In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received ... -
TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers.
(SPRINGERNATURE, 2024-04-17)Poor survival and lack of treatment response in glioblastoma (GBM) is attributed to the persistence of glioma stem cells (GSCs). To identify novel therapeutic approaches, we performed CRISPR/Cas9 knockout screens and ... -
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
(AMER ASSOC CANCER RESEARCH, 2020-10-01)PURPOSE: The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, and only a minority of patients benefit from checkpoint immunotherapy. Talimogene laherparepvec ... -
Tandem duplications contribute to not one but two distinct phenotypes.
(NATL ACAD SCIENCES, 2016-09-06) -
Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-β-Catenin Signaling.
(CELL PRESS, 2016-08-04)The poly(ADP-ribose) polymerase (PARP) Tankyrase (TNKS and TNKS2) is paramount to Wnt-β-catenin signaling and a promising therapeutic target in Wnt-dependent cancers. The pool of active β-catenin is normally limited by ... -
Target 2035 - update on the quest for a probe for every protein.
(ROYAL SOC CHEMISTRY, 2022-01-27)Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. The challenge of translating the wealth of new knowledge from genomics into new medicines ... -
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
(2018-10-15)Background Greater understanding of the molecular classification of breast cancer has permitted the development of rational drug design strategies. In a phase I clinical trial setting, molecular profiling with next-generation ... -
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
(2018-12)Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types.Observations ... -
Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
(WILEY, 2019-09-01)OBJECTIVES: To develop a focused panel of somatic mutations (SMs) present in the majority of urothelial bladder cancers (UBCs), to investigate the diagnostic and prognostic utility of this panel, and to compare the ...